๐๐ผ๐ป๐ด ๐ง๐ฒ๐ฟ๐บ ยฎโข
Maruti Suzuki 11000-12300 Expected level 16000 Support 9800
16700๐ฅLong term level hit
๐ฅ3
๐๐ผ๐ป๐ด ๐ง๐ฒ๐ฟ๐บ ยฎโข
Bajaj Auto 7400-8200 Expected level 9500 Support 6900
9700๐ฅLong term level hit
๐ฅ7โค1
Apollo Hospital Enterprise Ltd company details report
Apollo Hospital Enterprise Ltd (AHEL) is one of the leading integrated healthcare service providers in Asia. It has a presence in hospital, pharmaceutical, primary care & diagnostic clinics. It also has telemedicine units across 10 countries, health insurance services, global projects consultancy, colleges of nursing and hospital management and a research foundation, epidemiological studies, stem cell & genetic research. As on 31st March 2025, it has a total of 73 hospitals, of which 45 are owned including subsidiaries, JVs, and associates, 6 managed and 22 hospitals are towards cradles day surgeries (AHLL). The census bed capacity as on date is 10,187 beds with ~9,458 beds being operational. Besides its hospital-based pharmacies, AHEL runs pharmacy operations under the name โApollo Pharmacyโ through a retail pharmacy chain of 6,626 outlets as on 31st March 2025. Apollo Healthcare and Lifestyle (AHLL) subsidiary covers the retail healthcare business of the Apollo group, comprising Apollo Clinics, Apollo Sugar, White Dental, Apollo Day Surgery centres and Apollo Cradle.
Apollo Hospital Enterprise Ltd (AHEL) is one of the leading integrated healthcare service providers in Asia. It has a presence in hospital, pharmaceutical, primary care & diagnostic clinics. It also has telemedicine units across 10 countries, health insurance services, global projects consultancy, colleges of nursing and hospital management and a research foundation, epidemiological studies, stem cell & genetic research. As on 31st March 2025, it has a total of 73 hospitals, of which 45 are owned including subsidiaries, JVs, and associates, 6 managed and 22 hospitals are towards cradles day surgeries (AHLL). The census bed capacity as on date is 10,187 beds with ~9,458 beds being operational. Besides its hospital-based pharmacies, AHEL runs pharmacy operations under the name โApollo Pharmacyโ through a retail pharmacy chain of 6,626 outlets as on 31st March 2025. Apollo Healthcare and Lifestyle (AHLL) subsidiary covers the retail healthcare business of the Apollo group, comprising Apollo Clinics, Apollo Sugar, White Dental, Apollo Day Surgery centres and Apollo Cradle.
๐3๐1๐ฅ1
#SALES #GROWTH
FY25 has been a strong year for the company, continuing its momentum since the beginning of the financial year, followed by a double-digit growth across all three verticals. Sales grew by ~14% YoY to โน21,794 cr. Segment-wise, healthcare services grew by ~13% YoY (IP and OP volumes grew by ~7% and ~16% YoY); retail health & diagnostics by ~14% YoY, attributed to maturing network; digital health & pharmacy distribution by ~16% YoY, backed by growth in the omni channel pharmacy, followed by platform gross merchandise value (GMV) growth of ~8% YoY to ~โน3,007 cr. During the period, it added 607 pharmacy stores and closed 11 stores. With a net addition of 596 stores, the net count as on date stands at 6,626.
FY25 has been a strong year for the company, continuing its momentum since the beginning of the financial year, followed by a double-digit growth across all three verticals. Sales grew by ~14% YoY to โน21,794 cr. Segment-wise, healthcare services grew by ~13% YoY (IP and OP volumes grew by ~7% and ~16% YoY); retail health & diagnostics by ~14% YoY, attributed to maturing network; digital health & pharmacy distribution by ~16% YoY, backed by growth in the omni channel pharmacy, followed by platform gross merchandise value (GMV) growth of ~8% YoY to ~โน3,007 cr. During the period, it added 607 pharmacy stores and closed 11 stores. With a net addition of 596 stores, the net count as on date stands at 6,626.
โค2๐ซก2๐1๐ฅ1
#EBITDA #GROWTH
In FY25, EBITDA grew by ~26% YoY to โน3,022 cr, led by improved operating performance across hospitals and the HealthCo businesses. Segment-wise, EBITDA for hospitals stood at ~โน2,701 cr (v/s ~โน2,356 cr in FY24), diagnostics & retail health at ~โน154 cr (v/s ~โน117 cr in FY24). While the same for digital health & pharmacy distribution (excluding Apollo 24/7 operating costs) was โน754 cr (v/s ~โน626 cr in FY24). Apollo 24/7 operating cost stood at ~โน478 cr (including an ESOP non-cash charge of ~โน108 cr) v/s ~โน619 cr in FY24. Cost of raw material constituted ~13%, followed by other expenses ~22% (largely towards retainer fees to doctors and advertisements) and employee benefit expenses ~13%.
In FY25, EBITDA grew by ~26% YoY to โน3,022 cr, led by improved operating performance across hospitals and the HealthCo businesses. Segment-wise, EBITDA for hospitals stood at ~โน2,701 cr (v/s ~โน2,356 cr in FY24), diagnostics & retail health at ~โน154 cr (v/s ~โน117 cr in FY24). While the same for digital health & pharmacy distribution (excluding Apollo 24/7 operating costs) was โน754 cr (v/s ~โน626 cr in FY24). Apollo 24/7 operating cost stood at ~โน478 cr (including an ESOP non-cash charge of ~โน108 cr) v/s ~โน619 cr in FY24. Cost of raw material constituted ~13%, followed by other expenses ~22% (largely towards retainer fees to doctors and advertisements) and employee benefit expenses ~13%.
โก2๐2โค1
#PAT #GROWTH
In FY25, PAT grew by ~61% YoY to โน1,472 cr, driven by an improved topline and operating growth. Other income increased substantially by ~88% YoY to โน200 cr during the year. Segment-wise, PAT for hospitals was โน1,423 cr (v/s โน1,145 cr in FY24), diagnostics & retail health at negative โน27 cr (v/s negative โน51 cr in FY24). While the same for digital health & pharmacy distribution was โน47 cr (v/s negative โน196 cr in FY24), on account of optimization of cost and growth in operational revenue.
In FY25, PAT grew by ~61% YoY to โน1,472 cr, driven by an improved topline and operating growth. Other income increased substantially by ~88% YoY to โน200 cr during the year. Segment-wise, PAT for hospitals was โน1,423 cr (v/s โน1,145 cr in FY24), diagnostics & retail health at negative โน27 cr (v/s negative โน51 cr in FY24). While the same for digital health & pharmacy distribution was โน47 cr (v/s negative โน196 cr in FY24), on account of optimization of cost and growth in operational revenue.
๐1๐ฅ1๐1
#EBITDA #MARGIN
In FY25, EBITDA margin expanded by ~132 bps YoY to 13.9%. This was led by a decline in cost of materials consumed and other expenses as a percentage of sales. Segment-wise, EBITDA margins for the healthcare business was 24.2% (v/s 23.9% in FY24), diagnostics & retail health at 9.9% (v/s 8.5% in FY24). While the same for pharmacy distribution (excluding 24/7 operating cost) was 1.8%. The company has recruited additional doctors to boost volume and occupancy growth, restoring previous margin levels for the hospital business. Going forward, the focus will shift on cost efficiency, partially offset by the increased investment in Apollo 24/7.
In FY25, EBITDA margin expanded by ~132 bps YoY to 13.9%. This was led by a decline in cost of materials consumed and other expenses as a percentage of sales. Segment-wise, EBITDA margins for the healthcare business was 24.2% (v/s 23.9% in FY24), diagnostics & retail health at 9.9% (v/s 8.5% in FY24). While the same for pharmacy distribution (excluding 24/7 operating cost) was 1.8%. The company has recruited additional doctors to boost volume and occupancy growth, restoring previous margin levels for the hospital business. Going forward, the focus will shift on cost efficiency, partially offset by the increased investment in Apollo 24/7.
โก1โค1๐ฅ1๐ซก1
#ROCE
In FY25, ROCE for the company increased to 21.19%, aided by improving operating profit, despite increase in average capital employed. The company delivered a ROCE of 27.5% during FY25, with balanced ROCE across all geographies, including metros, tier 1 & tier 2 cities. Metro cities clocked in a ROCE of ~29% while that of non-metros was ~27%. Further, bed expansions and improvements in metrics across different regions helped in improving the operating profit and ROCE of the company.
In FY25, ROCE for the company increased to 21.19%, aided by improving operating profit, despite increase in average capital employed. The company delivered a ROCE of 27.5% during FY25, with balanced ROCE across all geographies, including metros, tier 1 & tier 2 cities. Metro cities clocked in a ROCE of ~29% while that of non-metros was ~27%. Further, bed expansions and improvements in metrics across different regions helped in improving the operating profit and ROCE of the company.
โค1๐1๐ฅ1๐ซก1
#ROE
In FY25, ROE increased to 20.51%, owing to rising net profit. The company has a focused presence towards different regions, offering services across hospitals, pharmacies, primary care & diagnostic clinics and several retail health chains. Strong patient volumes post-pandemic, improving GMV and cost efficiency drove the overall profit and improved the ROE. The company is foraying across new facilities which would help to widen its patient base. This will help in improving the profitability and maintaining strong return ratios of the company going ahead.
In FY25, ROE increased to 20.51%, owing to rising net profit. The company has a focused presence towards different regions, offering services across hospitals, pharmacies, primary care & diagnostic clinics and several retail health chains. Strong patient volumes post-pandemic, improving GMV and cost efficiency drove the overall profit and improved the ROE. The company is foraying across new facilities which would help to widen its patient base. This will help in improving the profitability and maintaining strong return ratios of the company going ahead.
๐ฅ1๐1๐ซก1